Preliminary results of a phase I study of intra-pleural injection of mesothelin-targeted chimeric antigen receptor T-cell (CAR-T) therapy, with or without anti-PD-1 agents, showed a 63% RR in 18 MM patients, 37% of which had already been treated with three or more lines of therapy [54]. Here, MSLN is linked to Miyoshi myopathy.